Insiders Don’t Lie: Mark Kuna Unloaded 22131 shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in an Insider Trade

November 25, 2016 - By Ruchi Gupta

Insiders Don't Lie: Mark Kuna Unloaded 22131 shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in an Insider Trade

Mark Kuna Insider Sell

The SVP & Controller of Orasure Technologies Inc, Mark Kuna has made a sudden transaction in the corporation that is worth $197,567 US Dollars. As reported in the Washington-based SEC legal report filed on 25/11/2016, Mark sold 22,131 shares at an average price-per-share of $8.9. Mark Kuna now has 72,965 shares of the Firm.

OraSure Technologies, Inc. (NASDAQ:OSUR) Ratings Coverage

Out of 5 analysts covering OraSure Technologies (NASDAQ:OSUR), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $10 is the highest target while $8 is the lowest. The $8.67 average target is -2.47% below today’s ($8.89) stock price. OraSure Technologies has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of OraSure Technologies, Inc. (NASDAQ:OSUR) has “Neutral” rating given on Monday, September 19 by BTIG Research. The rating was downgraded by Raymond James to “Market Perform” on Monday, June 13. The company was maintained on Thursday, August 4 by Jefferies. The stock of OraSure Technologies, Inc. (NASDAQ:OSUR) earned “Buy” rating by Mizuho on Thursday, November 5. The stock has “Buy” rating given by Canaccord Genuity on Wednesday, August 24.

Insitutional Activity: The institutional sentiment decreased to 1.06 in 2016 Q2. Its down 0.46, from 1.52 in 2016Q1. The ratio worsened, as 11 funds sold all OraSure Technologies, Inc. shares owned while 39 reduced positions. 25 funds bought stakes while 51 increased positions. They now own 43.86 million shares or 2.62% more from 42.75 million shares in 2016Q1.

Massachusetts Fincl Svcs Ma has 0% invested in the company for 220,926 shares. Janney Montgomery Scott Limited Liability Corporation last reported 0% of its portfolio in the stock. Public Employees Retirement Association Of Colorado reported 24,800 shares or 0% of all its holdings. Airain Ltd has invested 0.01% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR). Balyasny Asset Mgmt Ltd Liability Corporation has invested 0% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR). Blackrock Fund Advsrs holds 1.82 million shares or 0% of its portfolio. Moreover, Barclays Public Limited Co has 0% invested in OraSure Technologies, Inc. (NASDAQ:OSUR) for 7,056 shares. Geode Cap Limited Liability has invested 0% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR). Jpmorgan Chase And has 0% invested in the company for 557,324 shares. Deutsche Bancorporation Ag owns 72,759 shares or 0% of their US portfolio. Legal & General Group Public Limited Com, a United Kingdom-based fund reported 9,242 shares. The Ontario – Canada-based Hillsdale Inv has invested 0.09% in OraSure Technologies, Inc. (NASDAQ:OSUR). One Trading L P last reported 0% of its portfolio in the stock. Eam Invsts Lc holds 0.07% or 81,854 shares in its portfolio. Blackrock Gp holds 0% or 14,500 shares in its portfolio.

Insider Transactions: Since August 5, 2016, the stock had 0 buys, and 3 sales for $1.01 million net activity. 25,000 shares were sold by Michels Douglas A, worth $205,525. Another trade for 68,686 shares valued at $585,422 was made by JERRETT JACK E on Tuesday, August 30. Another trade for 26,308 shares valued at $217,722 was sold by Patrick Charles W.

About 176,658 shares traded hands. OraSure Technologies, Inc. (NASDAQ:OSUR) has risen 21.67% since April 22, 2016 and is uptrending. It has outperformed by 16.26% the S&P500.

OraSure Technologies, Inc. is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The company has a market cap of $493.78 million. The Firm also makes and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It has a 29.4 P/E ratio. The Company’s diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D.

According to Zacks Investment Research, “OraSure Technologies, Inc. is the market leader for oral fluid diagnostics. The Company develops, manufactures, and markets medical devices and diagnostic products for use by insurance companies, public health agencies, clinical laboratories, physicians’ offices, and workplace sites.”

Analysts await OraSure Technologies, Inc. (NASDAQ:OSUR) to report earnings on February, 1. They expect $0.05 EPS, down 37.50% or $0.03 from last year’s $0.08 per share. OSUR’s profit will be $2.78M for 44.45 P/E if the $0.05 EPS becomes a reality. After $0.11 actual EPS reported by OraSure Technologies, Inc. for the previous quarter, Wall Street now forecasts -54.55% negative EPS growth.

More news for OraSure Technologies, Inc. (NASDAQ:OSUR) were recently published by: Fool.com, which released: “Why OraSure Technologies, Inc Rose Today” on August 29, 2016. Fool.com‘s article titled: “Why OraSure Technologies, Inc is Jumping Today” and published on August 24, 2016 is yet another important article.

OSUR Company Profile

OraSure Technologies, Inc. (OraSure), incorporated on May 5, 2000, is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Firm also makes and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The Company’s diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. It sells over-the-counter (OTC) cryosurgical products to clients in North America, Europe, Central and South America, and Australia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>